Now Has 78 Patents Issued, Filed, Licensed or in Preparation As Taeus Commercial Launch Plans Advance
ANN ARBOR, MI / ACCESSWIRE / December 15, 2020 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued Chinese Patent ZL 2016 8 00267062 (the '062 patent) entitled "Systems and Methods for Imaging Biological Tissue Structures" from the Chinese Intellectual Property Office (SIPO). This is the seventh Chinese patent issued to ENDRA for its TAEUS technology.
"ENDRA's goal is to develop applications for our proprietary TAEUS technology in areas of high unmet clinical need and for which there are no practical existing tools. The recently issued ‘062 patent provides more robust intellectual property (IP) protection for our TAEUS platform in a key global market where an estimated 30% of its 1.4 billion citizens are affected by Non-Alcoholic Fatty Liver Disease," said Francois Michelon, ENDRA's chief executive officer.
The '062 patent structurally defines a hybrid integrated ultrasound/thermoacoustic system and method that locates and registers the ultrasound and thermoacoustic portions of the invention, relative to each other. It complements ENDRA's Chinese patent ZL 2016 8 00267289, which relates to an ultrasound/thermoacoustic system and method that utilizes separate ultrasound/thermoacoustic systems concurrently.
In the United States the parent application for the '062 patent has received a Notice of Allowance and is expected to issue in the first quarter of 2021, while a similar patent has already been issued in Europe as EP 3 294 142 B1.
"Receipt of the '062 patent is a key step forward in the development of optimized hybrid ultrasound and thermoacoustic imaging systems for a wide variety of clinical applications," added Michelon. "Our IP portfolio continues to grow and currently stands at 78 assets, including those in preparation, filed, issued and licensed."
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with the over 1 million ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, estimates of the timing of future events and achievements, such as the expectations regarding commercializing the TAEUS device, establishing evaluation reference sites and initial sales in Europe, receipt of U.S. Food and Drug Administration regulatory approval and expectations concerning ENDRA's business strategy. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of COVID-19 on our business plans; our ability to find and maintain development partners, market acceptance of our technology and the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this news release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
Investor Relations Contact:
Kim Sutton Golodetz
LHA Investor Relations
SOURCE: ENDRA Life Sciences Inc.